Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial
Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2019.03.017
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Elsevier BV